The Wegovy Pill Saw the Fastest Take-Up in Weight-Loss Drug History. Novo Nordisk only Narrowly Lifted Guidance.

Why It Matters

The rapid adoption of an oral GLP‑1 therapy could reshape obesity‑treatment dynamics and pressure pricing across the class, while Novo's modest guidance lift highlights the financial strain from price concessions and generic competition.

Key Takeaways

• Wegovy pill hit 200k weekly U.S. prescriptions
• Pill sales $350M, far below injectables
• Novo lifted guidance narrowly, profit decline persists
• Generic semaglutide entering India, Canada pressures pricing
• Expansion targets non‑U.S. markets in H2 2026

Pulse Analysis

The oral formulation of semaglutide, marketed as Wegovy pill, has shattered adoption benchmarks in the United States, reaching 200,000 weekly prescriptions by mid‑April. This pace eclipses any previous launch in the crowded GLP‑1 space, which includes injectable rivals such as Ozempic and Eli Lilly’s Mounjaro. Analysts attribute the rapid uptake to patient preference for a non‑injectable option and Novo Nordisk’s aggressive payer negotiations. While the pill generated roughly 2.26 billion Danish kroner in first‑quarter sales, it still trails the injectable line, underscoring the early stage of market penetration.

Despite the headline‑grabbing prescription volume, Novo Nordisk’s overall earnings picture remains constrained. Operating profit fell 15 percent to 32.82 billion kroner, and sales, adjusted for a U.S. pricing provision reversal, slipped 10 percent to 70.06 billion kroner. The company managed to beat profit forecasts, yet it only nudged its full‑year outlook upward, now projecting a 4‑12 percent decline versus a prior 5‑13 percent range. Pricing pressure is intensifying as the Most Favored Nations agreements in the United States and the imminent loss of exclusivity in several markets force lower realized prices.

Looking ahead, Novo Nordisk plans to roll out the Wegovy pill beyond the United States in the second half of 2026, aiming to capture market share before generic semaglutide gains traction in India and Canada. The expansion could offset some of the margin erosion caused by price concessions, but success will depend on navigating regulatory hurdles and convincing physicians to switch patients from injectables. For the broader GLP‑1 sector, the pill’s swift adoption signals a shift toward oral therapies, prompting competitors to accelerate their own oral pipelines and reevaluate pricing strategies in an increasingly price‑sensitive environment.